Clinical Trial: Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD

U.S., Aug. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07775950) titled 'Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD' on Aug. 16.

Brief Summary: This study aims to evaluate whether plasma molecular residual disease (MRD), assessed using circulating tumor DNA (ctDNA), can help optimize the duration of immunotherapy in patients with metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer.

Patients with MSI-H/dMMR metastatic colorectal cancer can achieve durable responses to immune checkpoint inhibitors, but the optimal duration of treatment remains uncertain. Prolonged immunotherapy may increase treatment bu...